Regenxbio Inc.

BioCentury’s latest Clinical Report highlights a pair of value-driving readouts

BioCentury’s latest Deals Report also includes Regenxbio/Nippon, Merus/Biohaven and Daiichi Sankyo/Glycotope

Genetic therapies compete in the same indications, as degraders come of age

New Year to put new obesity targets to the test, as all eyes on semaglutide in Alzheimer’s and launches in schizophrenia, AMD

Two gene therapies for Duchenne muscular dystrophy advance to Phase III as a preclinical program attracts pharma acquisition

Deal for up to $1.1B with ‘significant upfront payment’ rewards syndicate including Westlake and Versant, gives pharma three preclinical programs for muscular dystrophies

Plus: Ken Mills becomes CEO of Tagworks, and updates from AstronauTx, Trevi, Thrive and Madrigal

Plus: Structure strengthens team and updates from RegenxBio, Mirador, Abata, Entact, Nautilus and more

Gene therapy pioneer tells BioCentury his plans for his newcos GemmaBio and Franklin Biolabs

An inflection point for MPS, another controversy for DMD